A new discovery involving two Simon Fraser University scientists could lead to a little known and benign bacterium becoming a vital new tool in the development of a vaccine against human immunodeficiency virus (HIV).
Ralph Pantophlet, a Faculty of Health Sciences assistant professor, and Kate Auyeung, his senior research assistant and lab manager at SFU, and scientists in Italy have made a breakthrough discovery about Rhizobium radiobacter.
The journal Chemistry & Biology has just published their research in its Feb. 24 issue.
The research team has discovered this harmless bacterium has on its surface sugar molecules that resemble those on the surface of HIV. This resemblance gives scientists a basis for developing a preventive vaccine, putting our immune system on guard against HIV.
HIVs sugar molecules act as a cloaking device, preventing our immune system from detecting the virus until it has created several variant generations of itself. By the time our immune systems recognition has kicked in, weeks have elapsed, and HIV is several steps ahead of our bodys efforts to eliminate it.
Pantophlet and his colleagues believe the sugar molecules on Rhizobium radiobacter could be used to trigger our immune system to immediately recognize those on HIV, prompting more immediate awareness of the virus invasion.
The irony of our discovery is not lost on us, says Pantophlet. Weve found that a harmless species of a bacteria family that can cause tumours in the roots of legume plants could become a vital tool in the fight against one of the deadliest infectious diseases.
Before Rhizobium radiobacter can become the basis of an anti-HIV vaccine, the scientists need to find a protein to which they can attach the bacteriums sugar molecules. The protein is needed to properly trigger our immune systems development of antibodies to the sugar molecules. Such antibodies would then recognize and target HIVs sugar molecules because they resemble those on the bacterium.
This method of triggering antibodies development has led to the invention of successful sugar-based vaccines against diseases such as meningitis and childhood pneumonia.
Two known proteins, tetanus toxoid and CRM197, a nontoxic recombinant variant of diphtheria toxin, are commonly used to develop these kinds of vaccines, explains Pantophlet. So a lot of the groundwork is there for us to be able to have a vaccine that could be tested in a lab first and then in clinical trials later on.
Pantophlet and his colleagues are seeking grant funding from the Canadian Institutes for Health Research to continue their research.
If they get the grant, they hope to attach Rhizobium radiobacters sugar molecules to a protein and create vaccine candidates for testing within the next one to two years